Back Thorens B (1992) 'Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1', Proceedings of the National Academy of Sciences of the United States of America 89, 864145
Disclosures: Janet Chu: Gilead Sciences, Inc.: Grant/Research Support, Nghiem Ha: Nothing to Disclose, Mandana Khalili: gilead sciences: Grant/Research Support, GSK pharmaceuticals: Consultant, Intercept pharmaceuticals: Grant/Research Support, Gilead Sciences Inc: Consultant, Max Goldman: Eli Lilly: Stock - publicly traded company, Novo Nordisk: Stock - publicly traded company, Eli Lilly: Stock - publicly traded company, Madrigal: Stock - publicly traded company, Bilal Hameed: Gilead: Grant/Research Support, Intercept: Grant/Research Support, Pliant: Grant/Research Support, Novo Nordisk: Grant/Research Support, Madrigal: Grant/Research Support, Salix: Grant/Research Support, Mallinckrodt: Advisor, Pleiogenix: Advisor, CLDF: Advisor, Gilead: Consultant, Pioneering Medicine VII Inc: Consultant, Surrozen: Consultant, Pleiogenix: Stock privately held company, Scholars In Medicine: Speaking and Teaching, Rena Fox: Nothing to Disclose 1152 DIFFERENTIAL PROGNOSIS AND IMPACTS OF CARDIOMETABOLIC RISK FACTORS AND ALCOHOL INTAKE IN MASLD AND METALD PATIENTS Young Chang JAE YOUNG JANG 1 Soung Won Jeong 1 , 1 Soonchunhyang University Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD) are distinct yet overlapping conditions that significantly impact liver disease progression and mortality
Almost none of the ingredients in the formula have been observed to have a significant effect on resting metabolic rate in clinical studies
Hunter K, Hlscher C
